CANADA LIFE ASSURANCE Co Buys 38,269 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

CANADA LIFE ASSURANCE Co grew its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 74.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,861 shares of the biotechnology company’s stock after buying an additional 38,269 shares during the period. CANADA LIFE ASSURANCE Co owned 0.12% of Axon Enterprise worth $28,114,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of AXON. ICA Group Wealth Management LLC bought a new stake in shares of Axon Enterprise during the fourth quarter valued at approximately $26,000. Trivant Custom Portfolio Group LLC bought a new stake in Axon Enterprise in the first quarter worth $31,000. BKM Wealth Management LLC bought a new stake in Axon Enterprise in the fourth quarter worth $32,000. First PREMIER Bank bought a new stake in Axon Enterprise in the first quarter worth $33,000. Finally, Key Financial Inc increased its position in Axon Enterprise by 367.6% in the fourth quarter. Key Financial Inc now owns 159 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 125 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

Insiders Place Their Bets

In other Axon Enterprise news, Director Julie A. Cullivan sold 993 shares of the business’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $281.72, for a total value of $279,747.96. Following the completion of the transaction, the director now directly owns 4,553 shares in the company, valued at $1,282,671.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Axon Enterprise news, Director Julie A. Cullivan sold 993 shares of the business’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $281.72, for a total value of $279,747.96. Following the completion of the transaction, the director now directly owns 4,553 shares in the company, valued at $1,282,671.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeri Williams sold 308 shares of the business’s stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $310.07, for a total transaction of $95,501.56. Following the completion of the transaction, the director now owns 1,607 shares of the company’s stock, valued at $498,282.49. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 89,447 shares of company stock worth $27,684,677. 6.10% of the stock is owned by corporate insiders.

Axon Enterprise Stock Down 0.7 %

NASDAQ:AXON opened at $310.81 on Friday. Axon Enterprise, Inc. has a 1-year low of $175.37 and a 1-year high of $329.87. The company has a 50-day moving average of $294.06 and a 200 day moving average of $291.32. The firm has a market cap of $23.46 billion, a PE ratio of 90.88, a price-to-earnings-growth ratio of 7.06 and a beta of 0.95. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.91 and a quick ratio of 2.55.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Friday, May 10th. The biotechnology company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.20. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The company had revenue of $460.74 million during the quarter, compared to analyst estimates of $441.57 million. During the same period in the prior year, the firm earned $0.51 earnings per share. The firm’s revenue for the quarter was up 34.3% compared to the same quarter last year. As a group, research analysts anticipate that Axon Enterprise, Inc. will post 2.35 EPS for the current fiscal year.

Analysts Set New Price Targets

AXON has been the topic of several research reports. Barclays boosted their price target on shares of Axon Enterprise from $308.00 to $381.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 8th. William Blair reaffirmed an “outperform” rating on shares of Axon Enterprise in a research note on Wednesday, April 24th. Craig Hallum lifted their price objective on shares of Axon Enterprise from $325.00 to $370.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. JMP Securities reaffirmed a “market outperform” rating and set a $375.00 price objective on shares of Axon Enterprise in a research note on Tuesday, May 7th. Finally, Jefferies Financial Group assumed coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $385.00 price objective for the company. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $342.54.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.